Taneja SS - Search Results

1

Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer.

Sanfilippo NJ, Taneja SS, Chachoua A, Lepor H, Formenti SC. Sanfilippo NJ, et al. Among authors: taneja ss. J Clin Oncol. 2008 Jun 20;26(18):2973-8. doi: 10.1200/JCO.2007.14.4105. J Clin Oncol. 2008. PMID: 18565883 Clinical Trial.

2

Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder.

Li SM, Zhang ZT, Chan S, McLenan O, Dixon C, Taneja S, Lepor H, Sun TT, Wu XR. Li SM, et al. J Urol. 1999 Sep;162(3 Pt 1):931-5. doi: 10.1097/00005392-199909010-00093. J Urol. 1999. PMID: 10458411 Free article.

3

Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen.

Taneja SS, Penson DF, Epelbaum A, Handler T, Lepor H. Taneja SS, et al. J Urol. 1999 Oct;162(4):1352-7; discussion 1357-8. J Urol. 1999. PMID: 10492195 Clinical Trial.

4

Chemoprevention trials in men with prostate-specific antigen failure or at high risk for recurrence after radical prostatectomy: Application to efficacy assessment of soy protein.

Bosland MC, Kato I, Melamed J, Taneja S, Lepor H, Torre P, Walden P, Zeleniuch-Jacquotte A, Lumey LH. Bosland MC, et al. Urology. 2001 Apr;57(4 Suppl 1):202-4. doi: 10.1016/s0090-4295(00)00975-4. Urology. 2001. PMID: 11295628 Clinical Trial.

5

A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.

Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJ. Ko YJ, et al. Clin Cancer Res. 2001 Apr;7(4):800-5. Clin Cancer Res. 2001. PMID: 11309325 Clinical Trial.

6

A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.

Ferrari AC, Chachoua A, Singh H, Rosenthal M, Taneja S, Bednar M, Mandeli J, Muggia F. Ferrari AC, et al. Cancer. 2001 Jun 1;91(11):2039-45. Cancer. 2001. PMID: 11391583 Clinical Trial.

7

Volume-specific cutoffs are necessary for reproducible application of prostate-specific antigen density of the transition zone in prostate cancer detection.

Taneja SS, Tran K, Lepor H. Taneja SS, et al. Urology. 2001 Aug;58(2):222-7. doi: 10.1016/s0090-4295(01)01229-8. Urology. 2001. PMID: 11489705

8

Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling?

Lefkowitz GK, Sidhu GS, Torre P, Lepor H, Taneja SS. Lefkowitz GK, et al. Among authors: taneja ss. Urology. 2001 Dec;58(6):999-1003. doi: 10.1016/s0090-4295(01)01436-4. Urology. 2001. PMID: 11744476

9

Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.

Lefkowitz GK, Taneja SS, Brown J, Melamed J, Lepor H. Lefkowitz GK, et al. Among authors: taneja ss. J Urol. 2002 Oct;168(4 Pt 1):1415-8. doi: 10.1016/S0022-5347(05)64463-1. J Urol. 2002. PMID: 12352407

10

Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis.

Taneja SS, Hsu EI, Cheli CD, Walden P, Bartsch G, Horninger W, Babaian RJ, Fritsche HA, Childs S, Stamey TA, Sokoll LJ, Chan DW, Brawer MK, Partin AW, Lepor H. Taneja SS, et al. Urology. 2002 Oct;60(4 Suppl 1):10-7. doi: 10.1016/s0090-4295(02)01720-x. Urology. 2002. PMID: 12384157

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

681 results

Search Page

Filters